ArticleMolecular and clinical oncology2025
Perioperative nintedanib for lung resection in patients with idiopathic pulmonary fibrosis.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Care of the Patient with Interstitial Lung Disease Perioperatively.Current rheumatology reports · 2026Review
- Nintedanib Inhibits VEGF-Induced Neovascularization in Human Conjunctival Vascular Endothelial Cells.Current medical science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although nintedanib, an anti-fibrotic drug, relieves the chronological worsening of pulmonary function and prevents acute exacerbations of interstitial pneumonia, the perioperative safety and efficacy of nintedanib remains to be elucidated. The present study aimed to examine the safety and efficacy of nintedanib in patients with interstitial pneumonia. This study included 12 patients who underwent lung resection, including bilobectomy (n=2), lobectomy (n=7), segmentectomy (n=2) and wedge resection (n=1) between January 2020 and August 2023 at Juntendo University Nerima Hospital (Tokyo, Japan). Nintedanib was administered preoperatively to 10 male and two female patients with idiopathic pulmonary fibrosis and stage I to III lung cancer. The nintedanib dosing period ranged from 14 to 43 days. None of the patients canceled or postponed surgery because of side effects of nintedanib. Although prolonged air leak (n=3), surgical site infection (n=2), pyothorax (n=1), heart failure (n=1) and pleurisy (n=1) were observed postoperatively, the 30-day mortality rate was 0, with no acute exacerbation of interstitial pneumonia. These results encourage further investigation into the potential of nintedanib treatment in a larger patient cohort through prospective verification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.